Drugs / TAK-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04405778 | Jul 2020 → May 2025 | cancer | Takeda | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAK-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04405778 ↗ |
| Action | Inhibit | “TAK-102 is a medicine that sticks to GCP3 and stops it from working.” NCT04405778 ↗ |
| Modality | Cell therapy | “TAK-102 will be added to each person's white blood cells so is custom-made for each person.” NCT04405778 ↗ |
| Route | Intravenous | “Participants will receive TAK-102 with their cells slowly through a vein (infusion).” NCT04405778 ↗ |
| Target | GPC3 | “Some solid tumors make a lot of a protein called glypican 3(GPC3), which helps it to grow. Healthy cells and tissues do not make GPC3. TAK-102 is a medicine that sticks to GCP3...” NCT04405778 ↗ |